Mixed reality moves into the enterprise mainstream

Tern plc

A new phase of computing is taking shape as artificial intelligence and mixed reality converge. The shift from virtual to spatial computing marks the point where digital content no longer replaces reality but enhances it, and this time the technology is ready to scale.

Over the past ten years, immersive devices have moved through several hype cycles. Oculus, Vive, and Meta each pushed boundaries, but adoption stalled outside specialist sectors. Apple changed that dynamic with the launch of Vision Pro, positioning mixed reality as a serious computing platform rather than an entertainment accessory.

In parallel, AI has embedded itself across business software, creating intelligent systems that learn, predict, and respond to human needs. The merging of these two technologies is transformative. Mixed reality now has access to real-time understanding through AI, allowing devices to see, hear, and act on context. As hardware becomes lighter and socially acceptable, mixed reality glasses are set to evolve into all-day wearables that deliver live guidance, data access, and communication.

Meta’s display glasses with gesture control, Samsung and Google’s Moohan headset with Gemini AI, Amazon’s Jayhawk smart glasses for employees, and Apple’s Vision Air all signal a shared destination. By 2028, these devices will move into everyday enterprise use.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

Search